Cyclo Therapeutics : Corporate Presentation
NASDAQ: CYTH cyclotherapeutics.com Forward-Looking Statements 2 ...
Source: marketscreener.com
📰 Extension Study News
Extension Study News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Extension Study. Real-time updates on events, politics, business and more.
Cassava Sciences Reports Full-year 2023 Financial Results
$121.1 Million In Cash and Cash Equivalents at December 31, 2023, With an Additional $21.8 Million Raised In 2024 From Exercise of Warrants.A Total of Over...
Source: globenewswire.com
Istaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock SEISMiC Extension Study In Preparation For Phase 3 Readiness, Topline Data Expected Mid-2024
19.12.2023 - WARRINGTON, PA / ACCESSWIRE / December 19, 2023 / Windtree Therapeutics, Inc. (NASDAQ:WINT) has recently enrolled the first subject in its phase 2 SEISMiC Extension Study to evaluate istaroxime in the treatment of early cardiogenic shock. The phase ...
Source: wallstreet-online.de
Istaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock ...
Istaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock ...
News Network Windtree Therapeutics Inc Windtree Therapeutics Shock Requires Urgent Medical Treatment Has Significant Unmet Need Drug Treatment
Source: pr-inside.com
Clearside Biomedical's Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting -November 07, 2023 at 04:20 pm EST
ALPHARETTA, Ga., Nov. 07, 2023 -- Clearside Biomedical, Inc. , a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space ,...
United States George Lasezkay Jenny Kobin Triamcinolone Acetonide Suprachoroidal Remy Bernarda Belzupacap Sarotalocan
Source: marketscreener.com
Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting
- Excellent Safety Profile, Stable Vision, and Reduced Frequency of Injections Observed for up to 6 months – - ODYSSEY Phase 2b Clinical Trial Enrollment is On Track with Data Expected in Q3...
Source: marketscreener.com
Clearside Biomedical Positive OASIS and Extension Study
- Excellent Safety Profile, Stable Vision, and Reduced Frequency of Injections Observed for up to 6 months – - ODYSSEY Phase 2b Clinical Trial...
Source: globenewswire.com
Clearside Biomedical Announces First Quarter 2023 Financial Results and Provides Corporate Update
11.05.2023 - - Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected to Open Enrollment in Q2 2023 - - Positive Safety Data, Duration and Biologic Effect of CLS-AX Over 6 Months in OASIS Phase 1/2a Extension Study Highlighted in Presentations at Recent Medical ...
Source: wallstreet-online.de
Clearside Biomedical Presents Compelling Data at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting
ALPHARETTA, Ga., April 27, 2023 -- Clearside Biomedical, Inc. , a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space ,... | April 27, 2023
United States South Korea New Zealand Triamcinolone Acetonide Suprachoroidal Remy Bernarda Dennism Marcus
Source: marketscreener.com
Clearside Biomedical Announces Plans for ODYSSEY Phase 2b
- Multiple U.S. Clinical Sites to Begin Enrolling ODYSSEY Participants This Quarter - - ODYSSEY Topline Results Expected in Q3 2024 - ALPHARETTA, Ga.,...
George Lasezkay Jenny Kobin Remy Bernarda Exchange Commission Clearside Biomedical Inc Us Food Drug Administration
Source: globenewswire.com